- Dr. Sanjay Gupta
- Department of Urology, Case Western Reserve University, Cleveland, OH, USA.
Website | E-mail
Special Issue Introduction
Prostate cancer is the second leading cause of death in men and its development and progression is dependent on androgens/androgen receptor. The etiology of prostate cancer still remains elusive with genetic, epigenetic, environmental, and lifestyle factors associated with increased disease risk. The post-genome era research on prostate cancer has identified genetic variations associated with the disease including potential germline polymorphisms and allelic imbalances linked with prostate cancer susceptibility. Epigenetic mechanisms such as DNA hyper- or hypo- methylation, histone modifications and involvement of non-coding RNAs in gene transcription permit unchanging inheritance of phenotypes without changes in the DNA sequence. Such epigenetic modifications are developed as biomarkers for early detection, stratification and risk assessment of prostate cancer. In addition, current treatment options and novel drug combinations have strong potential for durable therapeutic responses and eventual cures for advanced disease. Improved disease management will also benefit from artificial intelligence-based decision support for disease prognosis and appropriate standard of care to minimize overtreatment of localized disease, and new standards of care augmented by next-generation adaptive clinical trials. The aim of this special issue on prostate cancer is to provide an updated knowledge on the epidemiology, etiology, diagnosis and treatment of prostate cancer.
ParticipantsShailesh Singh Morehouse School of Medicine, Atlanta, United States.
Xiaoqi Liu University of Kentucky, Lexington, United States.
Xiaolin Zi UCI Medical Center, Orange, United States.
Bruna Scaggiante Università degli Studi di Trieste, Trieste, Italy.
Pramod Kumar Julka Max Institute of Cancer Care, New Delhi, India.
Laurie M Connors Vanderbilt University, Nashville, United States.
Hari K. Koul LSU Health Sciences Center - Shreveport, Shreveport, United States.
Rong Na Fudan University, Shanghai, China.
Carlo Catapano Institute of Oncology Research IOR, Bellinzona, Switzerland.
Sharanjot Saini Augusta University, Augusta, United States.
samir Patra National Institute of Technology Rourkela, Rourkela, India.
Bodo C Melnik Universität Osnabrück, Osnabruck, Germany.
Susan Neuhausen City of Hope National Med Center, Duarte, United States.
Zhenyu Jia University of California, Riverside, Riverside, United States.
Roopa Biswas Uniformed Services University of the Health Sciences, Bethesda, United States.
Marina Ziche Università degli Studi di Siena, Siena, Italy.
Ganesh Raj UT Southwestern Medical Center, Dallas, United States.
Carlos Roggero UT Southwestern Medical Center, Dallas, United States.
Manoj Mishra Alabama State University, Montgomery, United States.
Richard Pestell Baruch S. Blumberg Institute, Doylestown, United States.
Anait S. Levenson Long Island University, New York, United States.
Ke Cao The Third Xiangya Hospital of Central South University, Changsha, China.
Ivan de Kouchkovsky University of California, San Francisco, San Francisco, United States.
The list is arranged in no particular order and being updated.
KeywordsProstate Cancer, genetics, epigenetics
Submission Deadline31 Mar 2021